Search

Your search keyword '"Franco Cosmi"' showing total 56 results

Search Constraints

Start Over You searched for: Author "Franco Cosmi" Remove constraint Author: "Franco Cosmi"
56 results on '"Franco Cosmi"'

Search Results

1. Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial

2. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

3. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

4. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

5. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial

6. 36-month clinical outcomes of patients with venous thromboembolism

7. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials

8. Imparare il metodo scientifico – Da Ippocrate a Garattini

9. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials

10. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

11. Te linee guida: la difficile applicazione tra clinica, scienza, giurisprudenza, sostenibilità economica ed organizzativa

12. Riflessioni su 'Arca Registry for Chronic Angina'

14. [Scientific communication to 'my' patient]

15. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

16. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure

17. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial

18. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

19. [Process to insulin for type 2 diabetes mellitus therapy]

20. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

21. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

22. Dexamethasone in acute cardiopulmonary syndrome with hyperinflammatory state

23. Stable atypical chest pain with negative anatomical or functional diagnostic test: Diagnosis no matter what or prevention at any cost?

25. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial

26. Looking for ischemia in patients with stable atypical chest pain: useful or useless?

27. A new odissey for the clinical cardiologist: the difficult application of arterial hypertension guidelines in patients with chronic coronary syndrome

28. [The patient in clinical research: disposable guinea pig or involved actor?]

29. Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial

30. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes

31. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

32. 2130The patient in clinical research: disposable guinea pig or involved actor?

33. P3706Atrial fibrillation with CHA2DS2-VASC =0. Really no need for anticoagulation?

35. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

37. [Medical intensive care unit patients with hyperglycemia: is it possible a hypoglycemic risk close to zero?]

39. Rivaroxaban with or without aspirin in patients with stable coronary artery disease : an international, randomised, double-blind, placebo-controlled trial

41. [Digitalis, a drug to be scrapped?]

43. Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial

44. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens

45. Randomized Comparison of Upstream Tirofiban Versus Downstream High Bolus Dose Tirofiban or Abciximab on Tissue-Level Perfusion and Troponin Release in High-Risk Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions

46. Combined Therapy with Benazepril and Amlodipine in the Treatment of Hypertension Inadequately Controlled by an ACE Inhibitor Alone

47. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial

49. [Metformin and insulin in chronic heart failure: contraindications not contraindicated and indications not indicated]

50. Clinical outcome of renal tubular damage in chronic heart failure

Catalog

Books, media, physical & digital resources